A single trial readout is reshuffling the mRNA vaccine trade this morning. BioNTech SE (NASDAQ:BNTX) stock is down 8% to $102.38 after the company terminated its Phase 2 colorectal cancer vaccine trial for futility,

Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase 3 win last week for their cancer vaccine plus Keytruda in melanoma.

Shares in the Mainz-based biotech tumbled 7.7 percent on Friday to EUR 88.30, extending the weekly decline to 12 percent. The stock now sits 17 percent below its 52-week high of EUR 105.80 reached in January, though it remains roughly 29 percent above the March trough of EUR 68.35.

In August 2026, Pfizer and BioNTech received U.S. FDA approval for their updated COMIRNATY COVID-19 vaccine targeting the XFG variant for high-risk individuals, while Pfizer and Valneva’s Lyme disease vaccine candidate PF-07307405 had its Marketing Authorization Application validated by the European Medicines Agency based on Phase 3 trial data.